Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial
Category: #health  By Mateen Dalal  Date: 2022-02-02
  • share
  • Twitter
  • Facebook
  • LinkedIn

Can Fite enrolls 1st patient in Phase IIb Namodenoson clinical trial

Can Fite BioPharma, an advanced clinical stage biotechnology company ramping up pipeline of its proprietary small molecule drugs designed for inflammatory, cancer and liver diseases, has reportedly announced the enrollment of first patient in its Phase IIb study of Namodenoson for non-alcoholic steatohepatitis (NASH).

The Phase IIb clinical trial of its drug candidate Namodenoson is a randomized, multi-center, double-masked, placebo-centered study conducted in subjects diagnosed with biopsy-confirmed NASH.

Primary assessment stage of the study will focus on evaluating the efficacy of Namodenoson against that of placebo among 140 subjects with NASH, as standardized by a histological endpoint.

As a part of the study, eligible subjects are randomly aligned in 2:1 ratio, offered either 25 mg of Namodenoson dose orally every 12 hours or similar pattern of placebo for 36 weeks.

As of now, not a single NASH treatment has been approved by the U.S. FDA, while the increasing prevalence of the condition is estimated to drive the potential pharmaceutical market to approximately $35-$40 billion by 2025.

The U.S. National Institutes of Health highlights that incidences of NASH in the U.S. are seen among 2-5% of the American population.

Moreover, NASH is at the forefront of causative factors for liver transplant in women and the second to lead cause in both men and women in the U.S., notably to flag itself as the leading position in causes for liver transplants in men as well.

Dr. Pnina Fishman, CEO of Can-Fite, explained that the Phase IIa study rendered promising results associated with key liver fibrosis and NASH biomarkers and hence the biopharma anticipates similar therapeutic effect among a larger cohort of subjects tested using liver biopsy.

Currently, Can-Fite has already secured out-licensing agreements for its proprietary drug Namodenoson in the treatment of NASH in China, Eastern Europe, and South Korea, consisting of milestone payments structure along with double-digit royalties following approval and commercialization.  

Source Credit: https://www.businesswire.com/news/home/20220131005278/en/Can-Fite-Announces-First-Patient-Enrolled-in-Phase-IIb-NASH-Clinical-Trial-with-Namodenoson

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Stocks of luxury fashion houses raise in response to China’s reopening
Stocks of luxury fashion houses raise in response to China’s reopening
By Mateen Dalal

Luxury fashion houses dependent on Chinese customers reportedly saw a hike in stocks as China reopens, however, those clients may not necessarily be purchasing the goods elsewhere. In the past, wealthy Chinese customers would frequently buy person...

Microsoft investigates Teams and Outlook outage that left users disrupted
Microsoft investigates Teams and Outlook outage that left users disrupted
By Mateen Dalal

Microsoft, the U.S.-based technology frontrunner, reportedly investigating an outage that prevented thousands of customers from accessing services like Teams and Outlook. Apparently, the tech giant did not disclose the number of users that were im...

DeHaat secures $60 million in funding, tops $700 million valuation
DeHaat secures $60 million in funding, tops $700 million valuation
By Mateen Dalal

Indian agritech firm DeHaat has reportedly raised $60 million in a new funding round as it looks forward to strengthening its footprint in the country and touching break-even profitability in two years. For the unversed, the startup provides a range ...